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COVID-19 is a respiratory infectious disease caused by SARS-CoV-2, and cardiovascular
damage is commonly observed in affected patients. We sought to investigate the effect of
SARS-CoV-2 infection on cardiac injury and hypertension during the current coronavirus
pandemic.
Study design and methods
The clinical data of 366 hospitalized COVID-19-confirmed patients were analyzed. The clini-
cal signs and laboratory findings were extracted from electronic medical records. Two inde-
pendent, experienced clinicians reviewed and analyzed the data.
Results
Cardiac injury was found in 11.19% (30/268) of enrolled patients. 93.33% (28/30) of cardiac
injury cases were in the severe group. The laboratory findings indicated that white blood
cells, neutrophils, procalcitonin, C-reactive protein, lactate, and lactic dehydrogenase were
positively associated with cardiac injury marker. Compared with healthy controls, the 190
patients without prior hypertension have higher AngII level, of which 16 (8.42%) patients
had a rise in blood pressure to the diagnostic criteria of hypertension during hospitalization,
with a significantly increased level of the cTnI, procalcitonin, angiotensin-II (AngII) than
those normal blood pressure ones. Multivariate analysis indicated that elevated age, cTnI,
the history of hypertension, and diabetes were independent predictors for illness severity.
The predictive model, based on the four parameters and gender, has a good ability to iden-
tify the clinical severity of COVID-19 in hospitalized patients (area under the curve: 0.932,
sensitivity: 98.67%, specificity: 75.68%).
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Conclusion
Hypertension, sometimes accompanied by elevated cTnI, may occur in COVID-19 patients
and become a sequela. Enhancing Ang II signaling, driven by SARS-CoV-2 infection, might
play an important role in the renin-angiotensin system, and consequently lead to the devel-
opment of hypertension in COVID-19.
Introduction
In December 2019, an acute respiratory infectious disease known as "coronavirus disease 2019
(COVID-19)" caused by a novel coronavirus occurred in Wuhan, China [1, 2]. Whole-genome
sequencing and systematic analysis showed that this novel. Coronavirus is a distinct clade
from beta coronavirus associated with human severe acute respiratory syndrome (SARS) and
Middle East respiratory syndrome (MERS) [3], and was now officially named "SARS-CoV-2"
by World Health Organization. Both SARS-CoV and SARS-CoV-2 have been identified to use
the angiotensin converting enzyme II (ACE2) receptor as the portal of entry into the affected
cell [4, 5]. ACE2, a membrane-bound aminopeptidase, is highly expressed in the heart and
lung [6, 7]. Although the main clinical features of COVID-19 are dominated by respiratory
symptoms, many patients with severe cardiovascular damage have been reported by our team
and others [8, 9]. Besides, patients with underlying cardiovascular diseases might have an
increased risk of death [8]. So, understanding the damage to the cardiovascular system caused
by SARS-CoV-2 and the underlying mechanisms is of great importance so that these patients
can be treated timely, and the mortality can be reduced. In this retrospective cohort study, the
clinical data of hospitalized COVID-19-confirmed patients were analyzed to explore the con-
sequences of SARS-CoV-2 infection on the cardiovascular system.
Materials and methods
Study setting and population
There were 366 COVID-19-confirmed patients enrolled in this study, who were hospitalized
in the Department of Infectious Diseases, Renmin Hospital of Wuhan University, from Feb-
ruary 1 to May 1, 2020. Clinical severity was defined for all enrolled COVID-19 patients
according to the guidelines of the National Health Commission of China, including four
types as mild, moderate, severe, and critical types [10]. We divided the patients into the non-
severe group (mild and moderate types) and the severe group (severe and critical type). Mild
type is defined as mild clinical symptoms and no pneumonia manifestation found in imaging.
Moderate cases refer to those who present with fever and respiratory tract symptoms, etc.
And have pneumonia manifestations found in imaging. Patients considered severe had one of
the following three conditions: respiratory distress and respiratory rate higher than 30 times
per minute; fingertip blood oxygen saturation less than 93% at rest; partial arterial oxygen
pressure (PaO2) / fraction of inspiration oxygen (FiO2) less than 300mmHg. Patients in criti-
cal type met one of the following criteria: respiratory failure, requiring mechanical ventila-
tion; shock; multiple organ failure, requiring intensive care management. This study was
reviewed and approved by the Medical Ethical Committee of Renmin Hospital of Wuhan
University. All participants provided written informed consent and agreed to use their medi-
cal records for research purposes.
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Data collection
The clinical signs and laboratory findings were extracted from electronic medical records
(Donghua Hospital Information System). Two independent, experienced clinicians reviewed
and abstracted the data. The recorded information includes demographic data, potential
comorbidities, symptoms, signs, laboratory test results. The serum level of hypersensitive tro-
ponin I (cTnI) exceeding >40 pg/mL was considered cardiac injury [11]. Blood pressures were
obtained three fixed times in the morning using standard measurement. History of hyperten-
sion was defined as brachial blood pressure� 140/90 mmHg or self-reported hypertension
medication use before hospitalization. For patients without prior hypertension, elevated blood
pressure was defined as blood pressure� 140/90 mmHg more than 3 times during
hospitalization.
The processes of patient screening
The screening process for evaluating the effect of SARS-CoV-2 on the cardiovascular system is
shown in Fig 1. Serum level of cardiac troponin I (cTnI) was tested in 276 of the 366 patients
during hospitalization, among which 8 patients had a history of chronic heart disease (includ-
ing ischemic heart disease, arrhythmia, valvular disease, and heart failure) and were therefore
excluded. Thus, 268 patients were enrolled to evaluate the effect of SARS-CoV-2 on cardiac
injury. Of the 366 patients, 278 had complete blood pressure data. Among these, 88 patients
had a history of hypertension before hospitalization and were excluded; therefore, 190 patients
were grouped to evaluate the effect of SARS-CoV-2 on blood pressure. Among all 366 subjects,
194 subjects had data available on serum level of cTnI and complete blood pressure data. After
Fig 1. The flow diagram of patient screening. Chronic heart disease includes ischemic heart disease, arrhythmia, valvular disease, and heart failure.
https://doi.org/10.1371/journal.pone.0250815.g001
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the exclusion of the case with a history of chronic heart disease, 186 cases were included to
evaluate the association between cTnI, blood pressure, and clinical severity of COVID-19.
Statistical analysis
Student’s t-test or the Mann-Whitney test was used to compare the mean of continuous vari-
ables, Fisher’s exact test was used with limited data, the χ2 test was used to compare the pro-
portion of categorical variables. Spearman correlation analysis was used to analyze the
correlation between variables. The logistic regression model was used to determine factors
associated with the clinical severity of COVID-19, and the analysis of receiver operating char-
acteristic (ROC) curves was constructed according to standard procedures. The Youden index,
defined as (sensitivity + specificity)– 1, was used to derive a reasonable cut-off value. Calibra-
tion of the risk prediction model, comparing the observed and predicted probability, was per-
formed via a visual calibration plot in the R program. A P-value of< 0.05 was considered
statistically significant. Statistical analysis was carried out using SPSS software version 21.0 and
R version 3.0.
Results
The effect of SARS-CoV-2 on cardiac injury
The results showed that the median age of patients with or without cardiac injury was 74 y/o
and 49 y/o with statistical significance (median [interquartile range]: 74 [73–86] vs. 49 [40–66]
y/o, p< 0.001). Males were dominant in the cardiac injury group (86.67%). The cardiac injury
was found in 11.19% (30/268) of patients, but 93.33% (28/30) of them were in the severe
group. The proportion of cardiac injury was significantly lower in the non-severe group
(1.75% vs. 18.18%, p< 0.001). Moreover, 66.67% (20/30) of cardiac injury patients in the
severe group eventually died. The most frequent symptom of patients was fever, followed by
cough, fatigue, dyspnea, and chest stuffiness. The incidences of cough, dyspnea, and chest
stuffiness were significantly different between the patients with or without cardiac injury
(93.33% vs. 68.91%, p = 0.005; 93.33% vs. 38.66%, p< 0.001; 86.67% vs. 36.97%, p< 0.001;
respectively). Hypertension was the most frequent comorbidity, while the incidence of diabetes
was significantly different between the two groups (33.33% vs. 14.29%, p = 0.017; Table 1).
The laboratory findings indicated that the patients who suffered from cardiac injury had a
higher level of white blood cells, neutrophils, monocytes, procalcitonin, C-reactive protein,
lactate, and lactic dehydrogenase compared with the patients without cardiac injury (median
[interquartile range]: 9.67 [5.62–13.73] vs. 5.93 [4.45–7.06] cells/L, p< 0.001; 5.52 [3.83–
11.62] vs. 3.72 [2.95–5.47] cells/L, p< 0.001; 0.62 [0.42–0.76] vs. 0.44 [0.25–0.69] cells/L,
p = 0.037; 630 [47.00–2750.00] vs. 60 [32.00–121.00] pg/mL, p< 0.001; 81.10 [14.20–142.80]
vs. 41.40 [5.00–74.40] mg/L, p< 0.001; 2.10 [1.95–3.05] vs. 1.70 [1.15–2.00] mmol/L, p<0.001;
428 [325.00–765.00] vs. 275 [218.00–375.00] U/L, p< 0.001; respectively). Correlation analysis
showed that white blood cells, neutrophils procalcitonin, C-reactive protein, lactate and lactic
dehydrogenase were significantly associated with cTnI, the r values were 0.515 [95% CI,
0.394–0.632], 0.486 [95% CI, 0.358–0.591], 0.477 [95% CI, 0.352–0.581], 0.459 [95% CI, 0.338–
0.566], 0.424 [95% CI, 0.273–0.559] and 0.438 [95% CI, 0.291–0.561], respectively (Table 2).
The effect of SARS-CoV-2 on blood pressure
Of the 190 qualified patients, 16 (8.42%) patients had a rise in blood pressure during hospitali-
zation, among which 6 patients were male, and 10 patients were female. As shown in Table 3,
no significant differences were found when comparing the baseline demographics, including
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age, gender, clinical category, symptoms, and comorbidities between patients with or without
elevated blood pressure. Compared with the patients without elevated blood pressure, the level
of cTnI and procalcitonin in the 16 patients rose significantly (median [interquartile range]:
Table 1. Clinical characteristics of COVID-19 patients with or without cardiac injury.
Total Cardiac injury
(n = 268) Non-injury (n = 238) Injury
(n = 30)
Age (y/o), Median (IQR) 53 (42–69) 49 (40–66) 74 (73–86)�§
Gender (n, %)
Male 144 (53.7) 118 (49.58) 26 (86.67)�£
Female 124 (46.3) 120 (50.42) 4 (13.33)�£
Clinical categories (n, %)
Non-severe 114 (42.54) 112 (47.06) 2 (6.67)�£
Severe 154 (57.46) 126 (52.94) 28 (93.33)�£
Symptoms (n, %)
Fever 224 (83.58) 196 (82.35) 28 (93.33)£
Cough 192 (71.64) 164 (68.91) 28 (93.33)�£
Dyspnea 120 (44.78) 92 (38.66) 28 (93.33)�£
Chest stuffiness 114 (42.54) 88 (36.97) 26 (86.67)�£
Fatigue 148 (55.22) 130 (54.62) 18 (60.00)£
Muscle soreness 54 (20.15) 48 (20.17) 6 (20.00)£
Comorbidities (n, %)
Hypertension 94 (35.07) 80 (33.61) 14 (46.67)£
Diabetes 44 (16.42) 34 (14.29) 10 (33.33)�#
Chronic lung diseases 10 (3.73) 8 (3.36) 2 (6.67)#
Chronic kidney diseases 4 (1.49) 2 (0.84) 2 (6.67)¶
Gastrointestinal diseases 2 (0.75) 2 (0.84) 0 (0)
Malignant tumor 4(1.49) 0 (0) 4 (13.33)
Student’s t-test, χ2 test, and Fisher’s exact tests were used to compare the age, gender, clinical category, symptoms, and comorbidities between the two groups (§ Two-
Sample T-test, £ Pearson’s chi-square test, # continuous correction Chi-square test, ¶ Fisher’s exact test).
�P < 0.05 is considered statistically significant.
https://doi.org/10.1371/journal.pone.0250815.t001
Table 2. The laboratory findings of COVID-19 patients with or without cardiac injury.
Laboratory findings Non-cardiac injury Cardiac injury Normal r values P-values
(median, IQR) (median, IQR) range
cTnI (pg/mL) 7.5 (6.00–16.50) 162 (68.20–757.50)� 0–40 1.000 < 0.001
White blood cells (×109 cells/L) 5.93 (4.45–7.06) 9.67 (5.62–13.73)� 3.5–9.5 0.515 < 0.001
Neutrophils (×109 cells/L) 3.72 (2.95–5.47) 5.52 (3.83–11.62)� 1.8–6.3 0.486 < 0.001
Lymphocytes (×109 cells/L) 1.01 (0.59–1.25) 0.67 (0.48–1.39)� 1.1–3.2 -0.230 0.001
Monocytes (×109 cells/L) 0.44 (0.25–0.69) 0.62 (0.42–0.76)� 0.1–0.6 0.127 0.080
Procalcitonin (pg/mL) 60 (32.00–121.00) 630 (47.00–2750.00)� 0–100 0.477 < 0.001
C-reactive protein (mg/L) 41.40 (5.00–74.40) 81.10 (14.20–142.80)� 0–10 0.459 < 0.001
Lactate (mmol/L) 1.70 (1.15–2.00) 2.10 (1.95–3.05)� 0.5–1.5 0.424 < 0.001
Lactic dehydrogenase (U/L) 275 (218.00–375.00) 428 (325.00–765.00)� 120–250 0.438 < 0.001
The Mann-Whitney test was used to compare the differences between non-cardiac injury and cardiac injury groups
�P <0.05 is considered statistically significant. Spearman correlation analysis was used to analyze the correlation between the cTnI and other laboratory findings.
https://doi.org/10.1371/journal.pone.0250815.t002
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22.00 [18.20–30.00] vs. 3.86 [2.49–5.15], p< 0.001; 82 [53–430] vs. 49 [28–73], p = 0.023;
Table 4). Elevated systolic blood pressure was observed in most of the patients, while diastolic
blood pressure was in the normal range. The median values of blood pressure and plasma
cTnI levels changes of the 16 patients are shown in Fig 2A. Systolic blood pressure and cTnI
Table 3. Clinical characteristics of COVID-19 patients without prior hypertension.
Total Blood pressure
(n = 190) Normal Elevated
(n = 16)(n = 174)
Age (y/o), Median (IQR) 54 (39–63) 53 (39–63) 60 (42–70)§
Gender (n, %)
Male 78 (41.05) 72 (41.38) 6 (37.50)£
Female 112 (58.95) 102 (58.62) 10 (62.50)£
Clinical categories (n, %)
Non-severe 116 (61.05) 108 (62.07) 8 (50.00)£
Severe 74 (38.95) 66 (37.93) 8 (50.00)£
Symptoms (n, %)
Fever 156 (82.11) 142 (81.61) 14 (87.50)#
Cough 132 (69.47) 120 (68.97) 12 (75.00)#
Dyspnea 70 (36.84) 64 (36.78) 6 (37.50)£
Chest stuffiness 68 (35.79) 62 (35.63) 6 (37.50)£
Fatigue 96 (50.53) 88 (50.57) 8 (50.00)£
Muscle soreness 36 (18.95) 34 (19.54) 2 (12.50)#
Comorbidities (n, %)
Diabetes 28 (14.74) 26 (14.94) 2 (12.50)#
Chronic lung diseases 6 (3.16) 6 (3.45) 0 (0)
Gastrointestinal diseases 4 (2.11) 4 (2.30) 0 (0)
Thyroid disease 2 (1.05) 2 (1.15) 0 (0)
Prostate disease 2 (1.05) 2 (1.15) 0 (0)
Student’s t-test, χ2 test, and Fisher’s exact tests were used to compare the age, gender, clinical category, symptoms, and comorbidities between the two groups (§ Two-
Sample T-test, £ Pearson’s chi-square test, # continuous correction Chi-square test). No significant differences were found.
https://doi.org/10.1371/journal.pone.0250815.t003
Table 4. The laboratory findings of patients with or without elevated blood pressure.
Laboratory findings Normal blood pressure Elevated blood pressure Normal range
(median, IQR) (median, IQR)
cTnI (pg/mL) 3.86 (2.49–5.15) 22.00 (18.20–30.00)� 0–40.00
White blood cells (×109cells/L) 5.24 (3.87–7.00) 4.86 (3.96–6.60) 3.50–9.50
Neutrophils (×109cells/L) 3.14 (2.48–4.96) 3.64 (3.06–4.94) 1.80–6.30
Lymphocytes (×109cells/L) 1.13 (0.76–1.56) 0.93 (0.57–1.23)� 1.10–3.20
Monocytes (×109cells/L) 0.44 (0.33–0.56) 0.55 (0.25–0.61) 0.10–0.60
Hemoglobin (g/L) 128 (118–136) 118(107–137) 115–150
Procalcitonin (pg/mL) 49 (28–73) 82 (53–430)� 0–100
C-reactive protein (mg/L) 20.00 (2.40–44.50) 7.80 (3.51–33.20) 0–10.00
Lactic dehydrogenase (U/L) 259 (206–313) 259 (208–289) 120–250
The Mann-Whitney test was used to compare the differences between non-hypertension and hypertension groups
�P <0.05 is considered statistically significant.
https://doi.org/10.1371/journal.pone.0250815.t004
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levels had a similar trend with the treatment time. In addition, the blood pressure, cTnI, and
white blood cells were continuously monitored in one index case (Fig 2B). With effective treat-
ment, the patient’s condition improved with regards to symptoms and as evident on chest CT.
Meanwhile, the systolic blood pressure and white blood cells reverted to the normal range, and
the concentrations of cTnI were also gradually decreased. Among the 190 patients without
prior hypertension, the serum levels of components in the renin-angiotensin system, including
adrenocorticotrophic hormone, renin, angiotensin II (Ang II), and aldosterone, were detected
in 28 patients. Comparison with healthy controls showed that AngII were significantly elevated
in both the normal and elevated blood pressure groups (median [interquartile range]: 137.12
[123.63–161.67] vs. 87.90 [48.23–107.39] pg/mL, p< 0.001; 169.25 [142.17–186.98] vs. 87.90
[48.23–107.39] pg/mL, p< 0.001; respectively; Table 5). When comparing the RAS between
the normal and elevated blood pressure groups, Ang II levels were significantly higher in the
latter group (median [interquartile range]: 169.25 [142.17–186.98] vs. 137.12 [123.63–161.67]
pg/mL, p = 0.020; Table 6).
The association between cardiac injury, blood pressure, and clinical
severity of COVID-19
Results of demographic and laboratory findings between the severe and non-severe group,
based on guidelines of the National Health Commission of China, are shown in Table 7.
Patients in the severe group were significantly older, with a greater proportion of males
(median [interquartile range]: 66 [57–76] vs. 42 [33–51] y/o, p< 0.001; 60.00% vs. 40.54%,
p = 0.009; respectively). In addition, the cTnI, white blood cells, neutrophils, procalcitonin, C-
reactive protein, and lactic dehydrogenase of the severe group were significantly higher than
those of the non-severe group (median [interquartile range]: 7.00 [5.78–27.00] vs. 5.68 [4.62–
6.45] pg/mL, p< 0.001; 5.98 [4.60–10.00] vs. 5.07 [3.65–6.00] ×109cells/mL, p = 0.004; 3.85
[3.02–8.27] vs. 2.67 [2.15–3.92] ×109 cells/mL, p< 0.001; 67.50 [32.00–288.00] vs. 36.00
[23.00–57.00] pg/mL, p = 0.005; 48.55 [7.40–81.50] vs. 6.20 [0.50–28.00] pg/mL, p<0.001;
316.00 [235.00–454.00] vs. 233.50 [187.50–292.00], p< 0.001; respectively). In contrast,
patients in the severe group had a significantly lower level of lymphocytes median [interquar-
tile range]: 0.78 [0.48–1.29] vs. 1.27 [0.96–1.73], ×109 cells/mL, p< 0.001). Further univariate
analysis revealed that the age, sex, cTnI, white blood cells, neutrophils, lymphocytes, C-reactive
Fig 2. A. The systolic blood pressure and cTnI change of patients with elevated blood pressure. B. The systolic blood pressure, cTnI,
white blood cells, and chest computed tomography changes of one patient with elevated blood pressure. Late follow-up: The 4th week
after discharge from the hospital.
https://doi.org/10.1371/journal.pone.0250815.g002
Table 5. The renin-angiotensin system in subjects with and without COVID-19.
Laboratory findings Healthy control Normal blood pressure Elevated blood pressure
(median, IQR) (median, IQR) (median, IQR)
Adrenocorticotrophic hormone (pg/mL) 31.92 (21.6–39.67) 27.55 (21.12–39.56)§ 33.03 (19.42–40.89)§
Renin (pg/mL) 5.31 (3.21–8.75) 6.35 (3.34–7.83)† 5.86 (4.41–6.76)†
Angiotensin II (pg/mL) 87.90 (48.23–107.39) 137.12. (123.63–161.67)�† 169.25 (142.17–186.98)�†
Aldosterone (pg/mL) 150.05 (129.32–164.32) 159.62 (119.16–169.30)† 141.54 (118.63–154.83)†
The normal and elevated blood pressure groups were compared with the healthy control group, respectively, by Student’s t test or the Mann-Whitney test (§ Two-
Sample T-test, † Mann Whitney U test/Wilcoxon Sum Rank test).
�P <0.05 is considered statistically significant.
https://doi.org/10.1371/journal.pone.0250815.t005
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protein, lactic dehydrogenase, and history of hypertension and diabetes were significantly
associated with the clinical severity of COVID-19. In the multivariate analysis, the age, cTnI
and history of hypertension and diabetes remained significant independent predictors
(OR = 1.11, 95% CI: 1.07–1.16, p< 0.001; OR = 1.08, 95% CI: 1.01–1.15, p = 0.018; OR = 7.19,
95% CI: 2.55–20.31, p< 0.001; OR = 4.28, 95% CI: 1.41–12.97, p = 0.010; Table 8). The
receiver operating characteristic curve of the four independent predictors and gender for clini-
cal severity of COVID-19 is shown in Fig 3A (AUC: 0.932, sensitivity: 98.67%, specificity:
75.68%). The calibration indicated that the model was well-calibrated (Fig 3B).
Table 6. The renin-angiotensin system in subjects with and without elevated blood pressure.
Laboratory findings Total Normal blood pressure Elevated blood pressure
(median, IQR) (median, IQR) (median, IQR)
Adrenocorticotrophic hormone (pg/mL) 30.56 (20.99–40.54) 27.55 (21.12–39.56) 33.03 (19.42–40.89)
Renin (pg/mL) 6.01 (4.15–7.46) 6.35 (3.34–7.83) 5.86 (4.41–6.76)
Angiotensin α (pg/mL) 153.67 (129.17–175.98) 137.12. (123.63–161.67) 169.25 (142.17–186.98)�
Aldosterone (pg/mL) 142.11 (119.16–163.28) 159.62 (119.16–169.30) 141.54 (118.63–154.83)
Student’s t test was used to compare the differences between normal and elevated blood pressure groups
�P <0.05 is considered statistically significant.
https://doi.org/10.1371/journal.pone.0250815.t006
Table 7. Clinical characteristics of severe and non-severe COVID-19 patients.
Clinical Severity Normal range
Non-severe Severe
(n = 111, 59.68%) (n = 75, 40.32%)
Age (y/o), Median (IQR) 42 (33–51) 66 (57–76)�§ -
Gender (n, %)
Male 45 (40.54) 45 (60.00)�£ -
Female 66 (59.46) 30 (40.00)�£ -
Clinical categories (n, %)
Elevated blood pressure 6 (5.41) 10 (13.33)£ -
Hypertension 15 (13.51) 20 (26.67)�£ -
Diabetes 7 (6.31) 21 (28.00)�£ -
Chronic lung diseases 7 (6.31) 10 (13.33)£ -
Chronic kidney diseases 2 (1.8) 2 (2.67)# -
Gastrointestinal diseases 2 (1.8) 1 (1.33)# -
Malignant tumor 2 (1.8) 0 (0) -
Laboratory findings
cTnI (pg/mL) 5.68 (4.62–6.45) 7.00 (5.78–27.00)�† 0–40.00
White blood cells (×109cells/L) 5.07 (3.65–6.00) 5.98 (4.60–10.00)�† 3.50–9.50
Neutrophils (×109cells/L) 2.67 (2.15–3.92) 3.85 (3.02–8.27)�† 1.80–6.30
Lymphocytes (×109cells/L) 1.27 (0.96–1.73) 0.78 (0.48–1.29)�† 1.10–3.20
Monocytes (×109cells/L) 0.42 (0.34–0.54) 0.44 (0.29–0.69)† 0.10–0.60
Procalcitonin (pg/mL) 36.00 (23.00–57.00) 67.50 (32.00–288.00)�† 0–100.00
C-reactive protein (mg/L) 6.20 (0.50–28.00) 48.55 (7.40–81.50)�† 0–10.00
Lactic dehydrogenase (U/L) 233.50 (187.50–292.00) 316.00 (235.00–454.00)�† 120–250
Student’s t test, Mann-Whitney test, χ2 test and Fisher’s exact tests were used to compare the age, gender, and clinical category between the two groups (§ Two-Sample
T-test, † Mann Whitney U test/Wilcoxon Sum Rank test, £ Pearson’s chi-square test, # continuous correction Chi-square test).
�P <0.05 is considered statistically significant.
https://doi.org/10.1371/journal.pone.0250815.t007
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Table 8. Univariate and multivariate analysis for clinical severity of COVID-19.
Odds ratio 95% CI P-value
Univariate analysis
Age (years) 1.12 1.09–1.15 <0.001�
Male (%) 2.20 1.21–4.00 0.010�
cTnI (pg/mL) 1.13 1.05 - 1.22 0.002�
White blood cells (×109cells/L) 1.39 1.13 - 1.70 0.002�
Neutrophils (×109cells/L) 1.50 1.19–1.90 0.001�
Lymphocytes (×109cells/L) 0.23 0.10–0.54 0.001�
Procalcitonin (pg/mL) 1.01 1.00–1.01 0.069
C-reactive protein (mg/L) 1.02 1.01–1.04 0.002�
Lactic dehydrogenase (U/L) 1.01 1.00–1.01 0.001�
Hypertension (%) 2.489 1.185–5.226 0.016�
Diabetes (%) 5.78 2.31–14.45 <0.001�
Multivariate analysis
Age (years) 1.11 1.07–1.16 <0.001�
Male (%) 1.38 0.57–3.37 0.479
CTnI (pg/mL) 1.08 1.01–1.15 0.018�
Hypertension (%) 7.19 2.55–20.31 <0.001�
Diabetes (%) 4.28 1.41–12.97 0.010�
The logistic regression model was used to determine factors associated with the clinical severity of COVID-19
according to Table 7
�P <0.05 is considered statistically significant.
https://doi.org/10.1371/journal.pone.0250815.t008
Fig 3. A. ROC curves of the age, cTnI, gender, and the presence of hypertension and diabetes for the identification of the severity of COVID-19. B. The calibration plot
for the comparison of the predicted and actual probability. The X-axis and Y-axis represent the model-predicted and actual probability of MAE, respectively. The red
line: perfect prediction. The black line: predictive performance of the model after bootstrapping (B = 1000 repetitions).
https://doi.org/10.1371/journal.pone.0250815.g003
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Discussion
SARS-CoV-2 has been identified as a single-stranded enveloped 39 RNA virus belonging to
the beta-coronavirus genus of the coronaviridae family [3]. These coronaviruses have a three-
dimensional spike protein structure protein, which can closely bind the human ACE2 recep-
tor. Therefore, the cells with ACE2 expression may act as target cells and be susceptible to
SARS-CoV-2 infection [12]. ACE2 is a membrane-bound aminopeptidase with a vital role in
the cardiovascular system [13, 14]. It is, therefore, reasonable to speculate that SARS-CoV-2
will act on the heart and blood vessels, with resultant changes in the cardiovascular system.
Serum cardiac troponin assays have been proposed as the recommended marker of cardiac
injury in COVID-19 patients [15]. Huang and colleagues find that cTnI is increased substan-
tially in 12.20% (5/41) Wuhan COVID-19 patients, in whom the diagnosis of the virus-related
cardiac injury is made [8]. Another previous research also reported that patients with cardiac
injury had higher levels of leukocyte counts, C-reactive protein, procalcitonin [16]. In this retro-
spective study, older patients with diabetes are more likely to suffer from cardiac injury. Our
further analysis shows that the level of white blood cells, neutrophils, procalcitonin, C-reactive
protein, lactate, and lactic dehydrogenase were positively associated with cardiac injury. Besides,
the cardiac injury occurred mostly in severe patients. Consequently, we hypothesize that the
severe type of COVID-19 characterized by acute inflammation response might be more prone
to cardiac injury, especially in patients with preexisting cardiovascular disease. Chronic myocar-
dial injury, acute nonischemic injury, and acute myocardial infarction have all been proposed
as causes of cTnI elevation in COVID-19 patients [17]. One case study suggested that direct
myopericardial involvement may be a complication of COVID-19 infection [18].
Understanding of the pathogenesis and complications of COVID-19 is still limited. Due to
the lack of viral load quantification results in the literature, it is unclear whether the cardiac
injury is directly related to viral load. The recent literature review has shown that although
cTnI concentration is only marginally increased in all patients with COVID-19, (values above
the 99th percentile upper reference limit in only 8–12% of positive patients), they are signifi-
cantly increased in patients with severe disease [19]. Our study further suggests that cardiac
injury is an independent risk factor for severe COVID-19 and in combination with age and
other statistically significant comorbidities can be used to construct a logistic regression model
of COVID-19 severity in hospitalized patients.
Sixteen patients without prior hypertension had a rise in blood pressure during hospitaliza-
tion, and higher systolic blood pressure was observed in most of the patients. Except for lym-
phocytes and procalcitonin, no significant differences are found in patients with and without
elevated blood pressure. This suggests that abnormal blood pressure may be caused indepen-
dently of the inflammatory response. The RAS plays a critical role in the cardiovascular system,
which includes a classical RAS axis (ACE-Ang II-AT1R pathway) and a non-classical RAS axis
(ACE2-Ang 1-7-MasR-based pathway), counter-balancing role of the two axes regulates car-
diovascular physiology and disease [20, 21]. ACE2 cleaves Ang II into the Ang 1–7, thus limit-
ing substrate availability in the adverse ACE/Ang II/AT1 receptor axis [22, 23]. Keidar and
colleagues found that ACE2 antihypertensive properties may be due to the degradation of
angiotensin II [24]. In this study, the laboratory results of RAS show that Ang II level is ele-
vated in the majority of patients without prior hypertension. Compared with normal blood
pressure and healthy control groups, Ang II levels were significantly higher in elevated blood
pressure groups. A possible mechanism may be the binding of SARS-CoV-2 to ACE2 thereby
inhibiting degradation of angiotensin II leading to elevated blood pressure. Another hypothe-
sis is that over activation of the RAS system promotes inflammatory response and cytokine
storm, which stimulates the NADH/NADPH oxidase system and triggers cell contraction and
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vasoconstriction, which then leads to COVID-19 related lung injury. Though the underlying
mechanism remains to be elucidated, it is becoming evident that RAS plays a major role in
hypertension and COVID-19 infection, as observed in our study. It has been noticed that
recombinant human ACE2 is considered as a treatment for patients with COVID-19 (Clinical-
Trials.gov ID: NCT04287686). This finding probably shades important implications for future
treatment strategies. A recent long-term observational follow-up study of patients with
COVID-19 reported nearly one-eighth of patients without previous renal dysfunction devel-
oped a reduction in glomerular filtration rate at follow-up. In addition, COVID-19 survivors
suffer from relatively higher levels of depression, anxiety, and somatic symptoms (including
fatigue or muscle weakness). Severe cases are more susceptible to the development of reduced
pulmonary diffusion capacities [25]. Multiple above factors are capable of inducing hyperten-
sion in nonhypertensive patients. In addition, the median ages of these patients were 66.5 y/o.
It seems that SARS-CoV-2 infection is just a trigger, and age plays a more important role.
On the other hand, sixteen patients with elevated blood pressure show significantly higher
levels of cTnI than those normal blood pressure patients. Several studies have demonstrated
Ang II direct or indirect effects on cardiomyocytes, some of which were related to pro-inflam-
matory and pro-hypertrophic responses [26]. Especially when the balance between the ACE
and ACE2 was disrupted in COVID-19 patients, the increase in Ang II actions could lead to
myocardial inflammation, oxidative stress, and myocyte apoptosis. This hypothesis explains
why elevated blood pressure could occur in parallel with mild cardiac injury of COVID-19
patients.
Study strength and limitations
In the present study, we propose that hypertension is probably a sequela of SARS-CoV-2 infec-
tion. Although a number of studies of COVID-19 have been reported, there are few reports
about the sequela of the disease likely due to lack of long-term clinical follow-up, which also
applies to our present research. Next, it is difficult to analyze whether the blood pressure of
COVID-19 patients with preexisting hypertension is further increased. Consequently, many
patients could not be incorporated in the analysis because of the history of hypertension,
which results in a relatively low sample size. Besides, the present study uncovered rising Ang II
as one possible mechanism that might result in hypertension in COVID-19. However, due to a
lack of detection about ACE2 levels and other components, therefore, we cannot gain a com-
prehensive view of virus-induced imbalance of the RAS pathway.
Conclusion
In summary, SARS-CoV-2 may impair cardiomyocytes by systemic acute inflammation
response, and the cTnI is correlated with the severity of the infection. Accompanied by mild
elevation in cTnI, spontaneous hypertension may occur in patients during hospitalization, and
could become a sequela of SARS-CoV-2 infection, which may be associated with markedly ele-
vated Ang II levels.
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